Epstein Becker Green attorneys successfully assisted their client, Dainippon Sumitomo Pharma Co., Ltd., in conducting health regulatory due diligence and negotiating a purchase agreement to be used in connection with the client's acquisition of Sepracor, a publicly-traded international pharmaceutical manufacturer. The purchase was valued at approximately $2.6 billion. This deal enables Dainippon, a Japanese pharmaceutical manufacturer, to expand its products into the U.S. market. The deal closed on October 14, 2009.
People
- Board of Directors / Member of the Firm
- Board of Directors / Member of the Firm